Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Thiogenesis Therapeutics Corp ( (TSE:TTI) ) has provided an announcement.
Thiogenesis Therapeutics announced that its abstract detailing preliminary Phase 2 clinical trial data for lead candidate TTI-0102 in patients with MELAS has been accepted as a Late-Breaking News presentation at the 2026 Mitocon conference in Pisa. The abstract, which will highlight pharmacokinetic and pharmacodynamic findings from the randomized, double-blind, placebo-controlled, multi-center trial, reinforces earlier biological proof-of-concept and biomarker activity supporting TTI-0102’s mechanism of action and underpins the company’s plans to advance the program, including an upcoming Phase 2a trial in Leigh syndrome spectrum, further solidifying its positioning in the rare mitochondrial disease space.
More about Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp. is a clinical-stage biopharmaceutical company based in San Diego, focused on developing next-generation sulfur-containing prodrugs as precursors to approved thiol-active compounds. Its lead candidate, TTI-0102, is designed to address mitochondrial dysfunction and oxidative stress in serious rare pediatric diseases such as MELAS and Leigh syndrome spectrum, reflecting a strategic emphasis on orphan mitochondrial and metabolic disorders with significant unmet medical need.
Average Trading Volume: 25,003
Technical Sentiment Signal: Sell
Current Market Cap: C$31.1M
See more insights into TTI stock on TipRanks’ Stock Analysis page.